10x Genomics, once a darling of the genomics instrumentation space, is confronting a capital efficiency reckoning that may signal deeper trouble for an entire class of AI-adjacent life science companies.
The company's financial trajectory has deteriorated sharply. Consumables revenue — the lifeblood of any instrumentation business — collapsed from $493.4 million to $122.2 million, while the annualized quarterly revenue run-rate has fallen to approximately $87.2 million, down from the $610.8 million pace that underpinned its growth-era valuation. The operating loss widened to $41.5 million even as gross margins improved from 67% to 72%, a troubling combination that suggests the company's cost structure is failing to adjust fast enough to a shrinking top line.
The balance sheet offers little comfort. Cash reserves have contracted from $482 million to $393.4 million, a drawdown that narrows the window for strategic pivots, acquisitions, or investment in new product cycles. At the current burn rate, the runway is finite and the pressure on management to demonstrate a credible path to profitability is intensifying.
Institutional Capital Is Choosing Sides
The timing of 10x Genomics' struggles is not coincidental. Institutional investors have been systematically reallocating capital toward pure-play AI infrastructure — companies like NVIDIA and Applied Materials, whose revenues are directly tied to the buildout of AI compute capacity. This concentration of capital in core AI plays has left companies that are AI-enabled but not AI-core facing a valuation vacuum.
Life science instrumentation companies like 10x Genomics occupy an awkward position in this landscape. Their platforms generate biological data that can feed machine learning pipelines, and their marketing has leaned heavily on AI integration narratives. But in a market where investors are drawing sharp distinctions between companies that sell the shovels for the AI gold rush and those that merely use AI-adjacent tools, the genomics sector is being repriced accordingly.
The pattern extends beyond genomics. 17 Education & Technology Group, another AI-adjacent technology company, saw its adjusted net loss margin deteriorate from -9.5% to -191%, suggesting that the valuation compression is not sector-specific but reflects a broader rerating of companies that sit at the periphery of the AI investment thesis.
The Valuation Multiple Question
Analysts tracking EV/Revenue multiples across technology subsectors are watching whether the divergence between core AI infrastructure and AI-adjacent companies widens further over the next two quarters. If AI-adjacent sectors — including genomics, edtech, and proptech — show more than 30% greater multiple compression than core AI infrastructure companies on a revenue-growth-adjusted basis, it would confirm a structural reallocation rather than a cyclical correction.
For 10x Genomics specifically, the challenge is operational as much as it is perceptual. The company must demonstrate that its spatial genomics and single-cell analysis platforms can generate durable, recurring revenue — the consumables model that drove its initial valuation story — while managing cash burn through a period of sector-wide skepticism.
With $393.4 million in cash remaining and losses widening, the clock is ticking. The next two earnings cycles will be critical in determining whether 10x Genomics can stabilize its revenue base or whether it becomes an early casualty of the AI capital concentration trade.